ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,454,573, issued on Oct. 28, was assigned to SYNOX THERAPEUTICS UK Ltd. (Oxford, Great Britain).
"Dosages of emactuzumab" was invented by Raymond Barlow (Dublin), Axel Mescheder (Dublin), Michael Cannarile (Penzberg, Germany) and Georgina Meneses-Lorente (Welwyn Garden City, Great Britain).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a treatment regime, including an antibody or antigen-binding fragment which is capable of binding specifically to colony stimulating factor-1 receptor (CSF-1R) for use in the treatment of tenosynovial giant cell tumour (TGCT) in a subject, as well as associated uses and methods."
The patent...